INTRODUCTION
Cytomegalovirus (CMV) infection is acquired throughout life. By age 50 years, -50% of the population in a developed country is seropositive for CMV. The clinical impact of infection differs by time of acquisition. Beyond the neonatal period, infection in the healthy patient is asymptomatic in -90% of cases. When clinical illness occurs, it is usually manifested as an infectious mononucleosislike syndrome, with atypical lymphocytosis but no heterophil antibody.
Although primary infection with CMV is usually benign, the virus remains latent within the host thereafter, as do all other herpesviruses. Under conditions of immune compromise, especially impairment of cell-mediated immunity, latent virus may reactivate to produce a variety of clinical syndromes, including chorioretinitis, esophagitis, colitis, pneumonia, encephalitis, and adrenalitis (9, 10) . Primary CMV infection is also severe (10) . CHORIORETIN1TIS Ocular disease due to CMV occurs only in patients with severe immunodeficiency and is especially common in patients with AIDS. Clinical evidence of CMV retinitis occurs in at least 5 to 10% of AIDS patients, and autopsy series have revealed that CMV retinitis is present in up to 30% of patients (3) . Retinitis is occasionally the presenting manifestation of AIDS but is more commonly present months to years after the diagnosis of AIDS has been established. Retinitis usually begins unilaterally, but progression to bilateral involvement is common. Systemic CMV infection is also frequently present, and viscera may be simultaneously diseased. Retinitis in the peripheral regions of the retina may be asymptomatic. The presence of "floaters," unilateral loss of visual field, or decreased visual acuity is the usual presenting complaint. Ophthalmologic examination typically reveals large, creamy to yellowish white granular areas with perivascular exudates and hemorrhages (referred to as "cottage cheese and catsup") ( Fig. 1) . The abnormalities may be found initially at the periphery of the fundus, but if left untreated, the lesions often progress to involve the macula and the optic disk. In some patients, the initial lesion is in or near the macula. Histologic examination reveals coagulation necrosis and microvascular abnormalities.
Differentiating suspected CMV retinitis lesions from cotton wool spots is essential. Cotton wool spots are small, fluffy white lesions with indistinct margins that are not associated with exudates or hemorrhages. They are common in AIDS patients but are asymptomatic. These Recently, a syndrome of progressive polyradiculopathy in patients with AIDS has been described (23) . Symptoms are notable for acute urinary retention and progressive flaccid paralysis in days to weeks, leading to being bedridden. ;t ' -;1 _-.1i;-_ .. 
DIAGNOSIS OF CMV INFECTION
The diagnosis of CMV infection can be substantiated by isolation of virus or seroconversion. A diagnosis of CMV disease is much more difficult to establish. For example, patients may excrete the virus in urine, semen, or cervical secretions for years following its acquisition. Thus, a positive culture from these sites does not, by itself, prove that CMV is the cause of the patient's current symptoms. Although recovery of the virus from the blood is suggestive of active disease due to CMV, patients may be asymptomatic even when viremic.
The presence of characteristic CMV inclusions in samples from intestinal or esophageal biopsies as well as in brain, liver, and adrenal tissues indicates end organ pathology and is the most definitive evidence that the virus is contributing to or responsible for disease. If no other pathogen is identified, CMV is probably responsible for the disease. However, the detection of viral inclusions is not a sine qua non for proving disease, because inclusions can be rare and therefore may be missed because of sampling error.
In the absence of inclusions, the presence of CMV antigen or in situ nucleic acid may help to define tissue invasion. In such cases a positive CMV culture can further substantiate the probability of CMV disease. However, culture may no longer be the gold standard of diagnosis. There appear to be instances in which detection of CMV antigen or CMV DNA or both in tissue represents a true positive, despite a negative culture.
Cytology and Histology
The microscopic hallmark of CMV infection is the large (cytomegalic) 25-to 35-,um cell containing a large, central, basophilic intranuclear inclusion. The inclusion is referred to as "owl's eye" because it is separated from the nuclear membrane by a halo. These inclusions are seen well with Papanicolaou or hematoxylin-eosin stain (Fig. 3) . Clusters of small intracytoplasmic inclusion may also be seen in CMVinfected cells. These inclusion are best seen with WrightGiemsa stain.
Cytologic and histologic observations are not sensitive measures of CMV infection. For (32) . On the basis of additional clinical and laboratory data, Spector et al. suggested that the cultures for their patients were false negative rather than that the hybridization assays were false positive (32) .
The polymerase chain reaction technique has been successfully applied to the diagnosis of CMV infection in blood and lungs (28) . This technique may in some instances be overly sensitive; i.e., it may detect nonreplicating virus that does not cause end organ damage.
Isolation of Virus
The yield of CMV from urine is increased two-to threefold by processing several specimens. Although infectivity can be well preserved for up to 7 days by storing specimens at 4°C, the virus is rapidly destroyed by freezing and thawing. Specimens should therefore be kept refrigerated, and they should be packed in wet ice for transport.
Urine specimens being cultured for CMV can be inoculated directly into cell culture medium. Some authorities have recommended that specimens be diluted to a strength of 1:2 or 1:3.3 (22) . Alternatively, specimens may be centrifuged, and the supernatant urine as well as the sediment resuspended in a small volume of urine can each be used as an inoculum. Since CMV grows only in human diploid fibroblast cell cultures, specimens for isolation must be inoculated into a cell line such as WI-38, MA-184, or Flow 2000. Cultures must be maintained for up to 6 weeks, since the characteristic cytopathic effect develops very slowly when titers are low.
In 1972, Anderson and Michaels (1) described the use of fluorescent-antibody staining of cell cultures to permit detection of CMV antigen prior to the development of cytopathic effect. The average time for detection of a positive culture by such staining was 3 days, and the technique was 86% as sensitive as conventional culture.
Recently, investigators at the Mayo Clinic and elsewhere have reported excellent correlation between an overnight cell culture method (shell vial assay), using fluorescent antibodies, and the standard culture procedure (16 This problem can be avoided by using an anticomplement immunofluorescence procedure (25) (14) .
Despite the pitfalls described here, seroconversion is usually an eXcellent marker for primary CMV infection. Although the incttbation period for CMV infection may be 3 to 4 weeks, acutely ill patients experiencing a first infection are usually seronegative when they first present. High titers of IgG antibody then develop in 1 to 2 weeks.
Since the processing of acute-and convalescent-phase sera does not provide a rapid diagnosis, considerable effort has been expended to develop a reliable assay for IgM antibody to CMV. The presence of CMV-specific IgM antibody may be helpful in indicating recent or active infection, especially when seroconversion has already occurred by the time the first blood specimen is obtained. Figure 4 shows the typical course of the development of IgM antibody during primary CMV infection. In primary CMV infection, IgM antibody generally develops and then disappears over a period of 6 to 9 months. It would be unusual for this antibody to be absent in an immunocompetent patient suspected of having acute primary CMV infection, especially after a week or more of illness.
In certain types of immunocompromised patients, the ability to mount an IgM response may be impaired by the disease itself or by the treatment for that disease; therefore, titers of IgM antibody may be falsely negative during active infection. In homosexual men, IgM antibody is so prevalent (>90% in our study) that it is far less useful as a positive diagnostic test, but its absence would also argue against acute primary infection (24). The high prevalence of IgM antibody in the sera of homosexual men is presumably a result of reactivation of CMV, although repeated exposure to different strains of the virus may account for its presence in some individuals (13) . Theoretically, CMV-specific IgM antibody should be useful for identifying infants with congenital CMV infection. Unfortunately, this test is neither sensitive nor specific in infants (33) and therefore is not as useful as a urine culture obtained at birth or within the first 2 to 3 weeks of life. CMV Antigen Detection Recently, detection of CMV antigen in peripheral blood has provided a rapid and accurate means of detecting CMV viremia. When monoclonal antibody directed against the immediate-early antigen of CMV was used, an immunofluorescence assay of peripheral blood was positive in all patients whose blood was culture positive (30) . This assay has the advantage of being completed within hours and appears to be both sensitive and specific.
TREATMENT OF CMV RETINITIS CMV retinitis in AIDS patients is progressive and generally leads to blindness if untreated (21) . Ganciclovir stabilizes or improves retinitis and vision in 75 to 85% of AIDS patients with the disease; the degree of improvement depends on the degree to which disease involves the macula (5) . If (Table 2) .
Early in the AIDS epidemic, a diagnosis of CMV retinitis was considered a preterminal event, with patients generally surviving less than 6 weeks after the diagnosis. In a recent series by Jabs et al. (20) , however, the median survival time after diagnosis ranged from 6 months for all patients to close to 1 year for those who responded to ganciclovir therapy.
Therapy is often complicated by severe neutropenia, which requires temporary discontinuation or dosage modifi- cation of ganciclovir in 25% of patients and complete discontinuation in 10% (11) ( (13) . It appears to have an initial efficacy similar to that of ganciclovir. The recommended dosage for maintenance is 60 to 90 mg/kg/day but an optimal maintenance regimen has yet to be determined. Its bone marrow toxicity is not as severe as that of ganciclovir, but it is nephrotoxic. It appears that CMV isolates resistant to ganciclovir maintain susceptibility to foscarnet, and clinical improvement was noted when patients harboring ganciclovir-resistant isolates were switched to foscarnet (21) . Studies are under way to determine the comparative safety and efficacy of this agent and to develop an effective dosing regimen.
TREATMENT OF GASTROINTESTINAL INFECTION Subjective impressions and anecdotes suggest that gastrointestinal CMV infection is responsive to ganciclovir. However, in bone marrow transplant recipients no statistically significant impact on clinical parameters was seen when ganciclovir was compared with placebo. In part, the failure to show an impact was because of a high rate of clinical improvement in the placebo recipients due to general supportive therapy (29) . This study did indicate an impressive antiviral effect due to ganciclovir. A similar study in AIDS patients again showed an impressive antiviral effect, but the impact on clinical features was only minimally greater than supportive therapy (9) . FUTURE DIRECTIONS Efforts are already under way to identify those immunocompromised patients who are at high risk of developing active CMV disease. These individuals would become candidates for suppression of their CMV infection prior to the development of clinical disease. Such suppression might be achieved with acyclovir, which is not effective in the therapy of CMV infection but may be effective in prophylaxis at a time when there is presumably a lower titer of virus in the patient. Other modalities for prevention include the use of ganciclovir in parenteral or, more conveniently, oral form if the latter can be shown to achieve effective antiviral levels in tissues and secretions. An additional possibility is the use of CMV immune globulin to enhance host antiviral activity. For these prophylactic regimens to be useful, it will be necessary to monitor patients by culture or direct detection procedures and to initiate prophylaxis when evidence of active infection is present. An example of such a strategy would be to screen all human immunodeficiency virus antibody-positive patients for CMV viruria. Once their CD4 lymphocyte count dips below 50/mm3, those individuals who are viruric would receive one of the above prophylactic antiviral agents in an effort to prevent the need to treat active CMV retinitis or other end organ disease. An effort such as this would require extreme cooperation between virology laboratories and physicians involved in the care of immunocompromised patients.
